BIOMAT Database Logo BIOMAT Database Logo

Mode of action of a mycobacterial water-soluble adjuvant, MAF3. 1979

Y Kumazawa, and K Mizunoe, and K Yasuhira

UI MeSH Term Description Entries
D006968 Hypersensitivity, Delayed An increased reactivity to specific antigens mediated not by antibodies but by sensitized T CELLS. Hypersensitivity, Tuberculin-Type,Hypersensitivity, Type IV,Tuberculin-Type Hypersensitivity,Type IV Hypersensitivity,Delayed Hypersensitivity,Delayed Hypersensitivities,Hypersensitivity, Tuberculin Type,Tuberculin Type Hypersensitivity,Tuberculin-Type Hypersensitivities,Type IV Hypersensitivities
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D006241 Haptens Small antigenic determinants capable of eliciting an immune response only when coupled to a carrier. Haptens bind to antibodies but by themselves cannot elicit an antibody response. Hapten,Contact-Sensitizing Agents,Agents, Contact-Sensitizing,Contact Sensitizing Agents
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody

Related Publications

Y Kumazawa, and K Mizunoe, and K Yasuhira
The adjuvant activity of a mycobacterial water soluble adjuvant (WSA) in vitro. I. The requirement of macrophages.
July 1974, Journal of immunology (Baltimore, Md. : 1950),
Y Kumazawa, and K Mizunoe, and K Yasuhira
[Antitumoral effect of peritoneal macrophages activated by a water-soluble adjuvant of mycobacterial origin].
May 1974, Comptes rendus hebdomadaires des seances de l'Academie des sciences. Serie D: Sciences naturelles,
Y Kumazawa, and K Mizunoe, and K Yasuhira
Activity in saline of phthalylated or succinylated derivatives of mycobacterial water-soluble adjuvant.
December 1976, Infection and immunity,
Y Kumazawa, and K Mizunoe, and K Yasuhira
Adjuvant formulations and their mode of action.
September 1990, Seminars in immunology,
Y Kumazawa, and K Mizunoe, and K Yasuhira
Inulin: A New Adjuvant With Unknown Mode of Action.
February 2017, EBioMedicine,
Y Kumazawa, and K Mizunoe, and K Yasuhira
QS-21: a water-soluble triterpene glycoside adjuvant.
September 1998, Expert opinion on investigational drugs,
Y Kumazawa, and K Mizunoe, and K Yasuhira
The mode of action of mycobacterial adjuvants. III. The clonal nature of antibody formation and the effect of mycobacterial adjuvant on antibody-forming cell clones.
August 1975, The Japanese journal of experimental medicine,
Y Kumazawa, and K Mizunoe, and K Yasuhira
[Adjuvant activity and antigenicity of MAF3 determined by the lymphocyte blastogenesis (author's transl)].
January 1978, Nihon saikingaku zasshi. Japanese journal of bacteriology,
Y Kumazawa, and K Mizunoe, and K Yasuhira
Distinctive adjuvanticity of synthetic analogs of mycobacterial water-soluble components.
February 1976, Cellular immunology,
Y Kumazawa, and K Mizunoe, and K Yasuhira
Water-soluble adjuvant obtained from Bacterionema matruchotii.
June 1978, Infection and immunity,
Copied contents to your clipboard!